ReviewDiabetes technology & therapeutics2021
What's Wrong with This Picture? A Critical Review of Current Centers for Medicare & Medicaid Services Coverage Criteria for Continuous Glucose Monitoring.
Review in Diabetes technology & therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 36 citations in OpenAlex.
- Challenges and Opportunities for Improving Care for Type 1 Diabetes in Older Adulthood.Diabetes care · 2026Review
- Who is using continuous glucose monitoring for type 2 diabetes management? A scoping review protocol.BMJ open · 2025Article
- An Ethical Framework for Addressing the Differential Impact of Systemic Racism and Inequities on Type 1 and Type 2 Diabetes Mellitus in Youth in the United States.Hormone research in paediatrics · 2025Review
- Expanding Access to Continuous Glucose Monitoring in Medicare Patients Receiving Specialty Diabetes Care: A Quality Improvement Project.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2025Article
- Expanding Access to Continuous Glucose Monitoring Through Empowering Primary Care: A Joint Endocrinology-Primary Care Quality Improvement Project.Journal of general internal medicine · 2025Article
- Best practices and rationale for expanding Medicaid access to continuous glucose monitoring.Journal of managed care & specialty pharmacy · 2024Article
- Innovation is the driver behind quality improvements in diabetes care delivery.Journal of managed care & specialty pharmacy · 2024Article
- Increase Access, Reduce Disparities: Recommendations for Modifying Medicaid CGM Coverage Eligibility Criteria.Journal of diabetes science and technology · 2024Article
- Benchmarking Diabetes Technology Use Among 21 U.S. Pediatric Diabetes Centers.Clinical diabetes : a publication of the American Diabetes Association · 2024Article
- Assessment and prevention of hypoglycaemia in primary care among U.S. Veterans: a mixed methods study.Lancet regional health. Americas · 2023Article
- Evaluating Factors Associated With Continuous Glucose Monitoring Utilization With the Type 1 Diabetes Exchange Registry.Journal of diabetes science and technology · 2023Article
- Diabetes Specialists Value Continuous Glucose Monitoring Despite Challenges in Prescribing and Data Review Process.Journal of diabetes science and technology · 2023Article
- Disparities in Continuous Glucose Monitoring Use Among Women of Reproductive Age with Type 1 Diabetes in the T1D Exchange.Diabetes technology & therapeutics · 2023Article
- Effect of CGM Access Expansion on Uptake Among Patients on Medicaid With Diabetes.Diabetes care · 2023Article
- The National Clinical Care Commission Report to Congress: Leveraging Federal Policies and Programs to Improve Diabetes Treatment and Reduce Complications.Diabetes care · 2023Review
- Article
- Advances in the management of type 2 diabetes in adults.BMJ medicine · 2023Review
- Roadmap to Achieving Continuous Glucose Monitoring Equity: Insights From the T1D Exchange Quality Improvement Collaborative.Diabetes spectrum : a publication of the American Diabetes Association · 2023Article
- Real-World Evidence Supporting Tandem Control-IQ Hybrid Closed-Loop Success in the Medicare and Medicaid Type 1 and Type 2 Diabetes Populations.Diabetes technology & therapeutics · 2022Article
- Barriers and Facilitators to Diabetes Device Adoption for People with Type 1 Diabetes.Current diabetes reports · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 8 institutions in 1 country.
Funding
Abstract
Numerous studies have demonstrated the clinical value of continuous glucose monitoring (CGM) in type 1 diabetes and type 2 diabetes populations. However, the eligibility criteria for CGM coverage required by the Centers for Medicare & Medicaid Services (CMS) ignore conclusive evidence that supports CGM use in various diabetes populations that are currently deemed ineligible. This article discusses the limitations and inconsistencies of the CMS eligibility criteria relative to current scientific evidence and proposes workable solutions to address this issue and improve the safety and care of all individuals with diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.